ERC Awards 10 Million Euros for Neuroblastoma Blood Test

Researchers Matthias Fischer and Martin Peifer will use the Synergy Grant to develop an early-detection blood test for the childhood cancer neuroblastoma.

Updated on Nov. 12, 2026 in Cancer

Clear glass test tubes holding pale red liquid sit in a rack on a steel laboratory bench, with a pipette resting across the foreground.
The European Research Council awarded researchers Matthias Fischer and Martin Peifer a 10 million euro Synergy Grant to develop an early blood test for childhood neuroblastoma. AI Illustration. Upload story photo >

Live Poll

Should governments fund more research into early detection of childhood cancers?

The European Research Council has awarded a 10 million euro Synergy Grant to Matthias Fischer and Martin Peifer for the EVO-DETECT project. The team aims to develop a blood test capable of detecting neuroblastoma before clinical diagnosis.

Why it matters

Neuroblastoma is one of the most common fatal cancers among children in Europe, and recovery chances for high-risk patients have not improved in recent years. Early detection could change outcomes for affected children and may serve as a model for tests in other cancers.

The Synergy Grant provides up to 10 million euros over six years, the maximum award under the program. The project will test the blood test using computer models, experimental systems and patient blood samples, but its clinical accuracy remains unknown until the research is complete.

The players

European Research Council

The European Research Council is an EU-funded body that supports frontier research through competitive grants awarded on scientific excellence.

Matthias Fischer

Matthias Fischer is a researcher at the University of Cologne who co-leads the EVO-DETECT project on neuroblastoma detection.

Martin Peifer

Martin Peifer is a researcher at the University of Cologne who co-leads the EVO-DETECT project on neuroblastoma detection.

The details

The EVO-DETECT team, which includes researchers from the University of Cologne, the German Cancer Research Centre in Heidelberg and the Institute Curie in Paris, will study how neuroblastoma evolves genetically and epigenetically from onset to high-risk tumour. Research suggests these tumours originate in the foetal stage and gradually become highly malignant.

Timeline

  1. The Synergy Grant funds the EVO-DETECT project over a six-year period.

Health Landscape

The EVO-DETECT project is funded through the European Research Council's Synergy Grant program, which backs collaborative research across institutions. The project's stated aim of a proof-of-concept early-detection test for other cancers reflects a broader push toward liquid-biopsy screening in oncology.

If the blood test is validated, it could allow families to learn of a neuroblastoma risk before symptoms appear, opening earlier treatment options. The project is still in research, so no screening or test is available to patients today.

The takeaway

Early detection research for childhood cancers depends on sustained, multi-country funding, and grants like this one are how promising blood-based approaches move from laboratory concept toward clinical testing. Readers should watch for published validation data before assuming any screening tool is available.

Further reading

Explore more on Cancer to see how early-detection research is shaping outcomes for children and adults.

Live Poll

Should governments fund more research into early detection of childhood cancers?